The untold story of the private equity investors behind Mifeprex—and their escalating legal battle to cash in post-Dobbs.
HANNAH LEVINTOVA
Mother Jones, MARCH+APRIL 2023 ISSUE
In 1993, a group of activists rented a warehouse in suburban Westchester County, New York. It was smaller than they’d hoped and had limited ventilation, but the two other locations they’d tried to rent belonged to universities and required jumping through too many bureaucratic hoops—the exact sort of paper trail this group was trying to avoid.
Led by renowned pro-choice activist Lawrence Lader, their goal was to replicate RU-486, the revolutionary abortion pill developed in the 1980s by French manufacturer Roussel-Uclaf—which was unwilling to navigate American abortion politics to bring the pill stateside.